BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003;63:2739-54. [PMID: 14664653 DOI: 10.2165/00003495-200363240-00004] [Cited by in Crossref: 117] [Cited by in F6Publishing: 102] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Hunt RH, Armstrong D, James C, Chowdhury SK, Yuan Y, Fiorentini P, Taccoen A, Cohen P. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol. 2005;100:1949-1956. [PMID: 16128938 DOI: 10.1111/j.1572-0241.2005.41956.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 50] [Article Influence: 3.3] [Reference Citation Analysis]
2 El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14:447-460. [PMID: 29620484 DOI: 10.1080/17425255.2018.1461835] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
3 Scholten T. Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag 2007;3:231-43. [PMID: 18360632 DOI: 10.2147/tcrm.2007.3.2.231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
4 Peyro Saint Paul L, Martin J, Buon M, Gaillard C, Fedrizzi S, Mosquet B, Coquerel A. [New frequent adverse reaction of PPI in older adults: mild hyponatremia]. Therapie 2014;69:157-62. [PMID: 24926634 DOI: 10.2515/therapie/2014019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
5 Giannini EG, Bilardi C, Dulbecco P, Mamone M, Santi ML, Testa R, Mansi C, Savarino V. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J Clin Gastroenterol. 2006;40:515-520. [PMID: 16825934 DOI: 10.1097/00004836-200607000-00010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
6 Zhang Y, Shi S, Liu Y, Chen X, Peng M. Differential effects of Cu(II) and Fe(III) on the binding of omeprazole and pantoprazole to bovine serum albumin: Toxic effect of metal ions on drugs. Journal of Pharmaceutical and Biomedical Analysis 2011;56:1064-8. [DOI: 10.1016/j.jpba.2011.08.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
7 Gabello M, Valenzano MC, Barr M, Zurbach P, Mullin JM. Omeprazole induces gastric permeability to digoxin. Dig Dis Sci. 2010;55:1255-1263. [PMID: 19513837 DOI: 10.1007/s10620-009-0851-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
8 Shaikh BA, Shaikh ZA, Shah AH, Kumar A. Determining the Risk of Spontaneous Bacterial Peritonitis due to increase use of Proton Pump Inhibitors among cirrhotic patients with ascites. Pak J Med Sci 2021;37:1075-9. [PMID: 34290786 DOI: 10.12669/pjms.37.4.3476] [Reference Citation Analysis]
9 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
10 Béïque L, Giguère P, la Porte C, Angel J. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med 2007;8:335-45. [PMID: 17661841 DOI: 10.1111/j.1468-1293.2007.00482.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
11 Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol 2013;14:150. [PMID: 23865955 DOI: 10.1186/1471-2369-14-150] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 6.9] [Reference Citation Analysis]
12 Zhang Y, Shi S, Huang K, Chen X, Peng M. Effect of Cu2+ and Fe3+ for drug delivery: Decreased binding affinity of ilaprazole to bovine serum albumin. Journal of Luminescence 2011;131:1927-31. [DOI: 10.1016/j.jlumin.2011.05.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
13 Robinson M. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications. Aliment Pharmacol Ther. 2004;20 Suppl 6:1-10. [PMID: 15496213 DOI: 10.1111/j.1365-2036.2004.02160.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
14 Berge M, Guillemain R, Trégouet DA, Amrein C, Boussaud V, Chevalier P, Lillo-Lelouet A, Le Beller C, Laurent-Puig P, Beaune PH, Billaud EM, Loriot MA. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Eur J Clin Pharmacol 2011;67:253-60. [PMID: 21038076 DOI: 10.1007/s00228-010-0914-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
15 Mccabe SM, Smith PF, Ma Q, Morse GD. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opinion on Drug Metabolism & Toxicology 2007;3:197-207. [DOI: 10.1517/17425255.3.2.197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
16 Robinson M. Proton pump inhibitors: update on their role in acid-related gastrointestinal diseases. Int J Clin Pract. 2005;59:709-715. [PMID: 15924600 DOI: 10.1111/j.1368-5031.2005.00517.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
17 Nageswara Rao R, Narasa raju A, Nagaraju D. Enantiospecific resolution of rabeprazole by liquid chromatography on amylose-derived chiral stationary phase using photo diode array and polarimetric detectors in series. Talanta 2006;70:805-10. [DOI: 10.1016/j.talanta.2006.01.042] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
18 Zhuang W, Li L, Lin G, Deng Z, Peng M. Ilaprazole metabolites, ilaprazole sulfone and ilaprazole sulfide decreased the affinity of ilaprazole to bovine serum albumin. Journal of Luminescence 2012;132:350-6. [DOI: 10.1016/j.jlumin.2011.09.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
19 Yurtsever AS, Pektas M, Ozkur M, Un I, Erenmemisoglu A, Buyukafsar K. Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter. Journal of Pharmacy and Pharmacology 2011;63:1295-300. [DOI: 10.1111/j.2042-7158.2011.01333.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Van de Steene JC, Mortier KA, Lambert WE. Tackling matrix effects during development of a liquid chromatographic-electrospray ionisation tandem mass spectrometric analysis of nine basic pharmaceuticals in aqueous environmental samples. J Chromatogr A 2006;1123:71-81. [PMID: 16720025 DOI: 10.1016/j.chroma.2006.05.013] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 5.4] [Reference Citation Analysis]
21 Wojnicz A, Gil García AI, Román-martínez M, Ochoa-mazarro D, Abad-santos F, Ruiz-nuño A. Improvement and Validation of a High-Performance Liquid Chromatography in Tandem Mass Spectrometry Method for Monitoring of Omeprazole in Plasma. Therapeutic Drug Monitoring 2015;37:381-8. [DOI: 10.1097/ftd.0000000000000155] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Trifirò G, Corrao S, Alacqua M, Moretti S, Tari M, Caputi AP, Arcoraci V; UVEC Group. Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. Br J Clin Pharmacol 2006;62:582-90. [PMID: 16822281 DOI: 10.1111/j.1365-2125.2006.02687.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
23 Vlase L, Popa A, Neag M, Muntean D, Leucuta SE. Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. Clin Drug Investig 2011;31:727-33. [PMID: 21877765 DOI: 10.2165/11589010-000000000-00000] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
24 Norman A, Hawkey CJ. What you need to know when you prescribe a proton pump inhibitor. Frontline Gastroenterol 2011;2:199-205. [PMID: 28839610 DOI: 10.1136/flgastro-2011-100006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
25 Ramakrishna N, Vishwottam K, Wishu S, Koteshwara M, Kumar SS. High-performance liquid chromatography method for the quantification of rabeprazole in human plasma using solid-phase extraction. Journal of Chromatography B 2005;816:209-14. [DOI: 10.1016/j.jchromb.2004.11.032] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
26 Du Y, Wu Y, Liu Y, Meng C, Tan L, Cai T, Wang Y, Lu Y. Identification and genotoxicity evaluation of potential impurities in rabeprazole sodium using in silico and in vitro analyses. Drug Chem Toxicol 2021;:1-7. [PMID: 33829945 DOI: 10.1080/01480545.2021.1908712] [Reference Citation Analysis]
27 Mori H, Tonai-Kachi H, Ochi Y, Taniguchi Y, Ohshiro H, Takahashi N, Aihara T, Hirao A, Kato T, Sakakibara M, Kurebayashi Y. N-(2-hydroxyethyl)-N,2-dimethyl-8-{[(4R)-5-methyl-3,4-dihydro-2H-chromen-4-yl]amino}imidazo[1,2-a]pyridine-6-carboxamide (PF-03716556), a novel, potent, and selective acid pump antagonist for the treatment of gastroesophageal reflux disease. J Pharmacol Exp Ther 2009;328:671-9. [PMID: 18981288 DOI: 10.1124/jpet.108.146415] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
28 Bradshaw TD, Bell DR. Relevance of the aryl hydrocarbon receptor (AhR) for clinical toxicology. Clin Toxicol (Phila) 2009;47:632-42. [PMID: 19640236 DOI: 10.1080/15563650903140423] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
29 Robinson M, Barone J. Review article: comparative pharmacodynamic review of rabeprazole - focus on day 1 data. Aliment Pharmacol Ther Symp Series 2006;2:315-26. [DOI: 10.1111/j.1746-6342.2006.00062.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Al-badr AA. Omeprazole. Elsevier; 2010. pp. 151-262. [DOI: 10.1016/s1871-5125(10)35004-7] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
31 Di Mario F, Cavallaro LG, Nouvenne A, Stefani N, Cavestro GM, Iori V, Maino M, Comparato G, Fanigliulo L, Morana E. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? Helicobacter. 2007;12:238-243. [PMID: 17493004 DOI: 10.1111/j.1523-5378.2007.00497.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 4.5] [Reference Citation Analysis]
32 Scholl S, Dellon ES, Shaheen NJ. Treatment of GERD and Proton Pump Inhibitor Use in the Elderly: Practical Approaches and Frequently Asked Questions. American Journal of Gastroenterology 2011;106:386-92. [DOI: 10.1038/ajg.2010.409] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
33 Watson JT, Moawad FJ, Veerappan GR, Bassett JT, Maydonovitch CL, Horwhat JD, Wong RKH. The Dose of Omeprazole Required to Achieve Adequate Intraesophageal Acid Suppression in Patients with Gastroesophageal Junction Specialized Intestinal Metaplasia and Barrett’s Esophagus. Dig Dis Sci 2013;58:2253-60. [DOI: 10.1007/s10620-013-2763-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
34 Zhu L, Persson A, Mahnke L, Eley T, Li T, Xu X, Agarwala S, Dragone J, Bertz R. Effect of Low-Dose Omeprazole (20 mg Daily) on the Pharmacokinetics of Multiple-Dose Atazanavir With Ritonavir in Healthy Subjects. The Journal of Clinical Pharmacology 2011;51:368-77. [DOI: 10.1177/0091270010367651] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
35 Solana MJ, López-Herce J. Pharmacokinetics of intravenous omeprazole in critically ill paediatric patients. Eur J Clin Pharmacol 2010;66:323-30. [PMID: 20041322 DOI: 10.1007/s00228-009-0774-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
36 Lou H, Yuan H, Ruan Z, Xu D, Zhou Q. LC Determination and Bioequivalence Study of Pantoprazole in Human Plasma. Chroma 2008;67:795-9. [DOI: 10.1365/s10337-008-0563-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
37 van Nuijs ALN, Tarcomnicu I, Simons W, Bervoets L, Blust R, Jorens PG, Neels H, Covaci A. Optimization and validation of a hydrophilic interaction liquid chromatography–tandem mass spectrometry method for the determination of 13 top-prescribed pharmaceuticals in influent wastewater. Anal Bioanal Chem 2010;398:2211-22. [DOI: 10.1007/s00216-010-4101-1] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 6.5] [Reference Citation Analysis]
38 Tachibana M, Hanaoka T, Watanabe S, Matsushita M, Isono T, Tsutsumi Y. Colitis nucleomigrans: The third type of microscopic colitis (part 1). Pathol Int 2020;70:752-60. [PMID: 32761850 DOI: 10.1111/pin.12996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Akkaif MA, Daud NAA, Sha'aban A, Ng ML, Abdul Kader MAS, Noor DAM, Ibrahim B. The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD). Molecules 2021;26:1987. [PMID: 33915807 DOI: 10.3390/molecules26071987] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
40 Souza FC, Baptista TM, Marques EB, Barros RB, Scaramello CB. Omeprazole does not modulate pharmacokinetic of digoxin in patients with heart failure. International Journal of Cardiology 2015;179:343-4. [DOI: 10.1016/j.ijcard.2014.11.062] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Dash RP, Rais R, Srinivas NR. Stereoselective and nonstereoselective pharmacokinetics of rabeprazole – an overview. Xenobiotica 2018;48:422-32. [DOI: 10.1080/00498254.2017.1307470] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
42 Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, Drouet E. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation. 2011;123:474-482. [PMID: 21262992 DOI: 10.1161/circulationaha.110.965640] [Cited by in Crossref: 118] [Cited by in F6Publishing: 43] [Article Influence: 10.7] [Reference Citation Analysis]
43 Mizokami Y, Yamamoto T, Atarashi H, Yamashita T, Akao M, Ikeda T, Koretsune Y, Okumura K, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Teramukai S, Kimura T, Kaburagi J, Takita A, Inoue H. Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry. PLoS One 2020;15:e0240859. [PMID: 33151969 DOI: 10.1371/journal.pone.0240859] [Reference Citation Analysis]
44 Sukhovershin RA, Cooke JP. How May Proton Pump Inhibitors Impair Cardiovascular Health? Am J Cardiovasc Drugs 2016;16:153-61. [PMID: 26817947 DOI: 10.1007/s40256-016-0160-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 4.4] [Reference Citation Analysis]
45 Belhocine K, Vavasseur F, Volteau C, Flet L, Touchefeu Y, Bruley des Varannes S. Controlling on-demand gastric acidity in obese subjects: a randomized, controlled trial comparing a single dose of 20 mg rabeprazole and 20 mg omeprazole. BMC Gastroenterol. 2014;14:128. [PMID: 25027286 DOI: 10.1186/1471-230X-14-128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Wynn GH, Sandson NB, Cozza KL. Gastrointestinal medications. Psychosomatics 2007;48:79-85. [PMID: 17209156 DOI: 10.1176/appi.psy.48.1.79] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
47 Fisher L, Fisher A. Acid-Suppressive Therapy and Risk of Infections: Pros and Cons. Clin Drug Investig 2017;37:587-624. [PMID: 28361440 DOI: 10.1007/s40261-017-0519-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
48 Gautam CS, Utreja A, Goel D, Sandhu G, Gogia N. Negative chronotropic effect of proton pump inhibitors on frog-heart preparation. Indian J Gastroenterol 2009;28:147-9. [PMID: 19937171 DOI: 10.1007/s12664-009-0052-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
49 Blandizzi C, Tuccori M, Colucci R, Gori G, Fornai M, Antonioli L, Ghisu N, Del Tacca M. Clinical efficacy of esomeprazole in the prevention and healing of gastrointestinal toxicity associated with NSAIDs in elderly patients. Drugs Aging. 2008;25:197-208. [PMID: 18331072 DOI: 10.2165/00002512-200825030-00003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
50 Litalien C, Théorêt Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005;44:441-66. [PMID: 15871633 DOI: 10.2165/00003088-200544050-00001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 59] [Article Influence: 4.4] [Reference Citation Analysis]
51 Zhang Y, Shi S, Peng M. Investigation of proton pump inhibitors binding with bovine serum albumin and their relationship to molecular structure. Journal of Luminescence 2012;132:1921-8. [DOI: 10.1016/j.jlumin.2012.03.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
52 Lloret Linares C, Declèves X, Oppert JM, Basdevant A, Clement K, Bardin C, Scherrmann JM, Lepine JP, Bergmann JF, Mouly S. Pharmacology of morphine in obese patients: clinical implications. Clin Pharmacokinet 2009;48:635-51. [PMID: 19743886 DOI: 10.2165/11317150-000000000-00000] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
53 Pascual J, Marcén R, Orea O, Navarro M, Alarcón M, Ocaña J, Villafruela J, Burgos F, Ortuño J. Interaction Between Omeprazole and Tacrolimus in Renal Allograft Recipients: A Clinical-Analytical Study. Transplantation Proceedings 2005;37:3752-3. [DOI: 10.1016/j.transproceed.2005.09.126] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
54 Singh H, Houy TL, Singh N, Sekhon S. Gastrointestinal prophylaxis in critically ill patients. Crit Care Nurs Q 2008;31:291-301. [PMID: 18815475 DOI: 10.1097/01.CNQ.0000336814.04548.ec] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
55 Abramenko N, Kejík Z, Kaplánek R, Tatar A, Brogyányi T, Pajková M, Sýkora D, Veselá K, Antonyová V, Dytrych P, Ikeda-Saito M, Martásek P, Jakubek M. Spectroscopic study of in situ-formed metallocomplexes of proton pump inhibitors in water. Chem Biol Drug Des 2021;97:305-14. [PMID: 32854159 DOI: 10.1111/cbdd.13782] [Reference Citation Analysis]
56 Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther 2008;6:785-96. [PMID: 19053892 DOI: 10.1586/14787210.6.6.785] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
57 Skrzydło-Radomańska B, Radwan P. Dexlansoprazole - a new-generation proton pump inhibitor. Prz Gastroenterol 2015;10:191-6. [PMID: 26759624 DOI: 10.5114/pg.2015.56109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
58 Baldwin CM, Keam SJ. Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2009;69:1373-401. [PMID: 19583455 DOI: 10.2165/00003495-200969100-00007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
59 Krens SD, Lubberman FJE, van Egmond M, Jansman FGA, Burger DM, Hamberg P, Vervenne WL, Gelderblom H, van der Graaf WTA, Desar IME, van Herpen CML, van Erp NP. The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. Int J Cancer 2021;148:2799-806. [PMID: 33428771 DOI: 10.1002/ijc.33469] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Zhang H, Zhang X, Liu J, Sun L, Shen Y, Zhou C, Zhang H, Xie L, Chen J, Liu Y, Wang Y. Effects of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of proton pump inhibitors. Pharmacological Research 2020;152:104606. [DOI: 10.1016/j.phrs.2019.104606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
61 Janett S, Camozzi P, Peeters GG, Lava SA, Simonetti GD, Goeggel Simonetti B, Bianchetti MG, Milani GP. Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors. Gastroenterol Res Pract 2015;2015:951768. [PMID: 26064102 DOI: 10.1155/2015/951768] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
62 Esplugues JV. A Pharmacological Approach to Gastric Acid Inhibition: . Drugs 2005;65:7???12. [DOI: 10.2165/00003495-200565001-00003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
63 Harding SM. Gastroesophageal Reflux During Sleep. Sleep Medicine Clinics 2007;2:41-50. [DOI: 10.1016/j.jsmc.2006.11.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
64 Soumekh A, Schnoll-sussman FH, Katz PO. Reflux and Acid Peptic Diseases in the Elderly. Clinics in Geriatric Medicine 2014;30:29-41. [DOI: 10.1016/j.cger.2013.10.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
65 Lai S, Lin C, Lin C, Liao K. Proton pump inhibitors therapy and the risk of hip fracture in older people in Taiwan. Eur Geriatr Med 2018;9:169-74. [DOI: 10.1007/s41999-017-0022-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
66 Mullin JM, Gabello M, Murray LJ, Farrell CP, Bellows J, Wolov KR, Kearney KR, Rudolph D, Thornton JJ. Proton pump inhibitors: actions and reactions. Drug Discov Today. 2009;14:647-660. [PMID: 19443264 DOI: 10.1016/j.drudis.2009.03.014] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
67 Ramakrishna N, Vishwottam K, Wishu S, Koteshwara M. High-performance liquid chromatography method for the quantification of pantoprazole in human plasma. Journal of Chromatography B 2005;822:326-9. [DOI: 10.1016/j.jchromb.2005.06.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
68 Scott SA, Owusu Obeng A, Hulot JS. Antiplatelet drug interactions with proton pump inhibitors. Expert Opin Drug Metab Toxicol 2014;10:175-89. [PMID: 24205916 DOI: 10.1517/17425255.2014.856883] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
69 Tolia V, Boyer K. Long-term proton pump inhibitor use in children: a retrospective review of safety. Dig Dis Sci 2008;53:385-93. [PMID: 17676398 DOI: 10.1007/s10620-007-9880-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
70 Hedaiaty M, Tamadon MR, Amiri A, Mahmoodnia L. Proton-pump inhibitors and risk of renal disease. J Nephropharmacol 2017;6:33-7. [DOI: 10.15171/npj.2017.02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
71 Balza E, Piccioli P, Carta S, Lavieri R, Gattorno M, Semino C, Castellani P, Rubartelli A. Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance. Cell Death Dis 2016;7:e2304. [PMID: 27441656 DOI: 10.1038/cddis.2016.218] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
72 Miyazaki Y, Ichimura A, Sato S, Fujii T, Oishi S, Sakai H, Takeshima H. The natural flavonoid myricetin inhibits gastric H + , K + -ATPase. European Journal of Pharmacology 2018;820:217-21. [DOI: 10.1016/j.ejphar.2017.12.042] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
73 Albsoul-younes A, Tayyem R, Najib N. Variable omeprazole kinetics in healthy Jordanian adults. Biopharm Drug Dispos 2005;26:183-8. [DOI: 10.1002/bdd.449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Tan JL, Eastment JG, Poudel A, Hubbard RE. Age-Related Changes in Hepatic Function: An Update on Implications for Drug Therapy. Drugs Aging 2015;32:999-1008. [DOI: 10.1007/s40266-015-0318-1] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 7.1] [Reference Citation Analysis]
75 Franciosi JP, Mougey EB, Williams A, Gomez-Suarez RA, Thomas C, Creech CL, George K, Corao D, Lima JJ. Association Between CYP2C19*17 Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux. J Clin Pharmacol 2018;58:89-96. [PMID: 28884817 DOI: 10.1002/jcph.977] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
76 Bamford M. 3 H+/K+ ATPase Inhibitors in the Treatment of Acid-Related Disorders. Progress in Medicinal Chemistry Volume 47. Elsevier; 2009. pp. 75-162. [DOI: 10.1016/s0079-6468(08)00203-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
77 Fang HM, Xu JM, Mei Q, Diao L, Chen ML, Jin J, Xu XH. Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. Acta Pharmacol Sin 2009;30:1566-72. [PMID: 19820718 DOI: 10.1038/aps.2009.142] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
78 Patel H, Desai N, Patel P, Modi N, Soni K, Patel JR, Mistry GN, Patel JD, Chawla M, Srinivas NR. Pharmacokinetic evaluation of differential drug release formulations of rabeprazole in dogs. Drug Dev Ind Pharm 2019;45:1459-67. [PMID: 31216902 DOI: 10.1080/03639045.2019.1628249] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Masclee GMC, Sturkenboom MCJM, Kuipers EJ. A Benefit–Risk Assessment of the Use of Proton Pump Inhibitors in the Elderly. Drugs Aging 2014;31:263-82. [DOI: 10.1007/s40266-014-0166-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
80 Ivashkin VT, Maev IV, Trukhmanov AS, Lapina TL, Storonova OA, Zayratyants OV, Dronova OB, Kucheryavyy YA, Pirogov SS, Sayfutdinov RG, Uspenskiy YP, Sheptulin AA, Andreev DN, Rumyantseva DE. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2020;30:70-97. [DOI: 10.22416/1382-4376-2020-30-4-70-97] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 8.5] [Reference Citation Analysis]
81 Deshpande N, V S, V V RK, H V V M, M S, Banerjee R, Tandan M, D NR. Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors. Meta Gene 2016;9:159-64. [PMID: 27419077 DOI: 10.1016/j.mgene.2016.06.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
82 Solana García MJ, López-Herce Cid J, Sánchez Sánchez C. Gastroesophageal reflux in critically ill children: a review. ISRN Gastroenterol 2013;2013:824320. [PMID: 23431462 DOI: 10.1155/2013/824320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Esplugues JV, Martí-Cabrera M, Ponce J. [Safety of proton pump inhibitors]. Med Clin (Barc) 2006;127:790-5. [PMID: 17198667 DOI: 10.1157/13095825] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
84 Gau J, Heh V, Acharya U, Yang Y, Kao T. Uses of proton pump inhibitors and serum potassium levels: PROTON PUMP INHIBITOR AND SERUM POTASSIUM LEVEL. Pharmacoepidem Drug Safe 2009;18:865-71. [DOI: 10.1002/pds.1795] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
85 Ratelle M, Perreault S, Villeneuve JP, Tremblay L. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol 2014;28:330-4. [PMID: 24945188 DOI: 10.1155/2014/751921] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
86 Ratelle M, Perreault S, Villeneuve JP, Tremblay L. Association between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascites. Can J Gastroenterol Hepatol. 2014;28:330-334. [PMID: 24945188 DOI: 10.1155/2014/751921] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
87 Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V. Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial. JAMA Oncol. 2017;3:767-773. [PMID: 27737436 DOI: 10.1001/jamaoncol.2016.3358] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
88 Moreira Dias L. Pantoprazole: a proton pump inhibitor. Clin Drug Investig 2009;29 Suppl 2:3-12. [PMID: 19938880 DOI: 10.2165/1153121-S0-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
89 Mares-García E, Palazón-Bru A, Folgado-de la Rosa DM, Pereira-Expósito A, Martínez-Martín Á, Cortés-Castell E, Gil-Guillén VF. Construction, internal validation and implementation in a mobile application of a scoring system to predict nonadherence to proton pump inhibitors. PeerJ 2017;5:e3455. [PMID: 28674646 DOI: 10.7717/peerj.3455] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
90 Schillinger W, Teucher N, Sossalla S, Kettlewell S, Werner C, Raddatz D, Elgner A, Tenderich G, Pieske B, Ramadori G, Schöndube FA, Kögler H, Kockskämper J, Maier LS, Schwörer H, Smith GL, Hasenfuss G. Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. Circulation 2007;116:57-66. [PMID: 17576869 DOI: 10.1161/CIRCULATIONAHA.106.666008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
91 Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011;12:873-888. [PMID: 21692617 DOI: 10.2217/pgs.11.4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
92 Mullin JM, Valenzano MC, Whitby M, Lurie D, Schmidt JD, Jain V, Tully O, Kearney K, Lazowick D, Mercogliano G. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther. 2008;28:1317-1325. [PMID: 18684245 DOI: 10.1111/j.1365-2036.2008.03824.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 4.4] [Reference Citation Analysis]
93 Shao F, Sun J, Wang G, Xie H, Zhu X, Zhang J. Liquid chromatographic–mass spectrometry analysis and pharmacokinetic studies of a novel rabeprazole formulation, sterile powder for injection, in dogs and rats. Biopharm Drug Dispos 2007;28:177-86. [DOI: 10.1002/bdd.543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
94 Miyamoto S, Tsuda M, Kato M, Mabe K, Muto S, Ono S, Shimizu Y, Sakamoto N. Evaluation of gastric acid suppression with vonoprazan using calcium carbonate breath test. J Clin Biochem Nutr 2019;64:174-9. [DOI: 10.3164/jcbn.18-75] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
95 Chheda NN, Postma GN. Patient Compliance with Proton Pump Inhibitor Therapy in an Otolaryngology Practice. Ann Otol Rhinol Laryngol 2008;117:670-2. [DOI: 10.1177/000348940811700907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
96 Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295-314. [PMID: 21822447 DOI: 10.1586/ecp.09.8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
97 Yang Y, George KC, Shang WF, Zeng R, Ge SW, Xu G. Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies. Drug Des Devel Ther 2017;11:1291-9. [PMID: 28479851 DOI: 10.2147/DDDT.S130568] [Cited by in Crossref: 34] [Cited by in F6Publishing: 11] [Article Influence: 6.8] [Reference Citation Analysis]
98 Roche VF. The chemically elegant proton pump inhibitors. Am J Pharm Educ. 2006;70:101. [PMID: 17149430 DOI: 10.5688/aj7005101] [Cited by in Crossref: 54] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
99 Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, Lindhardsen J, Madsen JK, Køber L, Torp-Pedersen C. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690. [PMID: 21562004 DOI: 10.1136/bmj.d2690] [Cited by in Crossref: 125] [Cited by in F6Publishing: 102] [Article Influence: 11.4] [Reference Citation Analysis]
100 Chan GC, Wong SH, Ng JK, Li PK, Szeto CC, Chow KM. Risk of peritonitis after gastroscopy in peritoneal dialysis patients. Perit Dial Int 2021;:8968608211018608. [PMID: 34032173 DOI: 10.1177/08968608211018608] [Reference Citation Analysis]
101 Rakesh TP. Proton pump inhibitors: use, misuse and concerns about long-term therapy. Clin J Gastroenterol 2011;4:53-9. [DOI: 10.1007/s12328-011-0208-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
102 Casciaro M, Navarra M, Inferrera G, Liotta M, Gangemi S, Minciullo PL. PPI adverse drugs reactions: a retrospective study. Clin Mol Allergy 2019;17:1. [PMID: 30675130 DOI: 10.1186/s12948-019-0104-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
103 Verstuyft C, Simon T, Kim RB. Personalized medicine and antiplatelet therapy: ready for prime time? European Heart Journal 2009;30:1943-63. [DOI: 10.1093/eurheartj/ehp295] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
104 Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors - focus on pKa and metabolism. Aliment Pharmacol Ther Symp Series 2006;2:340-50. [DOI: 10.1111/j.1746-6342.2006.00065.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
105 Lee CH, Franchi F, Angiolillo DJ. Clopidogrel drug interactions: a review of the evidence and clinical implications. Expert Opin Drug Metab Toxicol 2020;16:1079-96. [PMID: 32835535 DOI: 10.1080/17425255.2020.1814254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]